Wei Y, Li W, Huang J, Braunstein Z, Liu X, Li X
Theranostics. 2024; 14(3):1168-1180.
PMID: 38323310
PMC: 10845203.
DOI: 10.7150/thno.87130.
van Schaik P, Zuhorn I, Baron W
Int J Mol Sci. 2022; 23(15).
PMID: 35955549
PMC: 9368816.
DOI: 10.3390/ijms23158418.
Heng A, Han C, Abbott C, McColl S, Comerford I
Front Immunol. 2022; 13:817473.
PMID: 35250997
PMC: 8889115.
DOI: 10.3389/fimmu.2022.817473.
Ruan Y, Kim H, Ogana H, Gang E, Li S, Liu H
Exp Ther Med. 2021; 23(1):47.
PMID: 34934426
PMC: 8652384.
DOI: 10.3892/etm.2021.10969.
Wyatt N, Speight R, Stewart C, Kirby J, Lamb C
BioDrugs. 2021; 35(5):473-503.
PMID: 34613592
DOI: 10.1007/s40259-021-00496-5.
Cell Adhesion Molecules: Implications for Neurological Disease.
Fields R
Neuroscientist. 2019; 4(1):4-8.
PMID: 31467472
PMC: 6714583.
DOI: 10.1177/107385849800400107.
Brain vascular heterogeneity: implications for disease pathogenesis and design of in vitro blood-brain barrier models.
Noumbissi M, Galasso B, Stins M
Fluids Barriers CNS. 2018; 15(1):12.
PMID: 29688865
PMC: 5911972.
DOI: 10.1186/s12987-018-0097-2.
Integrins in T Cell Physiology.
Bertoni A, Alabiso O, Galetto A, Baldanzi G
Int J Mol Sci. 2018; 19(2).
PMID: 29415483
PMC: 5855707.
DOI: 10.3390/ijms19020485.
Integrins as Therapeutic Targets: Successes and Cancers.
Raab-Westphal S, Marshall J, Goodman S
Cancers (Basel). 2017; 9(9).
PMID: 28832494
PMC: 5615325.
DOI: 10.3390/cancers9090110.
The novel α4B murine α4 integrin protein splicing variant inhibits α4 protein-dependent cell adhesion.
Kouro H, Kon S, Matsumoto N, Miyashita T, Kakuchi A, Ashitomi D
J Biol Chem. 2014; 289(23):16389-98.
PMID: 24755217
PMC: 4047406.
DOI: 10.1074/jbc.M114.553610.
Dose-dependent anti-inflammatory and neuroprotective effects of an ανβ3 integrin-binding peptide.
Han S, Zhang F, Hu Z, Sun Y, Yang J, Davies H
Mediators Inflamm. 2013; 2013:268486.
PMID: 24347822
PMC: 3855988.
DOI: 10.1155/2013/268486.
Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action.
Damal K, Stoker E, Foley J
Biologics. 2013; 7:247-58.
PMID: 24324326
PMC: 3854923.
DOI: 10.2147/BTT.S53007.
How natalizumab binds and antagonizes α4 integrins.
Yu Y, Schurpf T, Springer T
J Biol Chem. 2013; 288(45):32314-32325.
PMID: 24047894
PMC: 3820868.
DOI: 10.1074/jbc.M113.501668.
Monoclonal antibodies as disease modifying therapy in multiple sclerosis.
Longbrake E, Parks B, Cross A
Curr Neurol Neurosci Rep. 2013; 13(11):390.
PMID: 24027005
PMC: 3967547.
DOI: 10.1007/s11910-013-0390-z.
The role of natural killer cells in multiple sclerosis and their therapeutic implications.
Chanvillard C, Jacolik R, Infante-Duarte C, Nayak R
Front Immunol. 2013; 4:63.
PMID: 23493880
PMC: 3595639.
DOI: 10.3389/fimmu.2013.00063.
Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.
Wolf C, Sidhu J, Otoul C, Morris D, Cnops J, Taubel J
PLoS One. 2013; 8(3):e58438.
PMID: 23472197
PMC: 3589412.
DOI: 10.1371/journal.pone.0058438.
Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis.
Chen Q, Massague J
Clin Cancer Res. 2012; 18(20):5520-5.
PMID: 22879387
PMC: 3473104.
DOI: 10.1158/1078-0432.CCR-11-2904.
Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis.
Gan Y, Liu R, Wu W, Bomprezzi R, Shi F
J Neuroimmunol. 2012; 247(1-2):9-15.
PMID: 22503411
PMC: 3351567.
DOI: 10.1016/j.jneuroim.2012.03.011.
Structural specializations of α(4)β(7), an integrin that mediates rolling adhesion.
Yu Y, Zhu J, Mi L, Walz T, Sun H, Chen J
J Cell Biol. 2012; 196(1):131-46.
PMID: 22232704
PMC: 3255974.
DOI: 10.1083/jcb.201110023.
Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab.
Patti F, Pappalardo A
Clinicoecon Outcomes Res. 2011; 1:45-51.
PMID: 21935306
PMC: 3169988.
DOI: 10.2147/ceor.s6665.